Loading patent…
AssigneeAmorfix Life Sciences Ltd.
InventorsNeil R. Cashman, Avijit Chakrabartty, Rishi Rakhit, Joachim Bernhard Ostermann
Estimating the term…
The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1. In addition, the invention includes methods of diagnosing Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis in a subject. Also, the invention provides methods of identifying substances for the treatment or prevention of Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis and kits using the binding proteins of the invention.
A method for treating ALS in a subject in need of treatment, the method comprising administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an exogenous antibody or antigen-binding fragment thereof that binds selectively and at least 2 fold more efficiently to a misfolded form of wild type human SOD1 compared to a natively folded form of wild type human SOD1, wherein the ALS is sporadic ALS.
A process for preparing an antibody, comprising the steps of (1) obtaining an immunogen comprising all or part of an isolated peptide consisting of a DSE1 or DSE1a epitope, the part comprising at least 5 contiguous residues;
A pharmaceutical composition useful in the treatment of a subject having ALS, the composition comprising a pharmaceutically acceptable vehicle and an isolated antibody comprising a human constant region, or antigen-binding fragment thereof, that binds selectively and at least 2 fold more efficiently to a misfolded form of wild type human SOD1 compared to a natively folded form of wild type human SOD1.
An isolated antibody or antigen binding fragment thereof that binds selectively to an isolated peptide corresponding to the DSE1a, or DSE1 epitope.
An isolated antibody or antigen-binding fragment thereof that binds selectively to an epitope wherein the epitope is a DSE4, DSE5, DSE6 or DSE7 epitope.
A hybridoma deposited with the International Depositary Authority in Winnipeg, Canada under accession no. 220207-01.
A hybridoma deposited with the International Depositary Authority in Winnipeg, Canada under accession no. 220207-02.
A hybridoma deposited with the international Depositary Authority in Winnipeg, Canada under accession no. 280207-01.
Dependencies are inferred from the claim text.